Интеграция генетических факторов риска и лекарственно-ассоциированных генов при терапии биполярного расстройства: биоинформатический и системно-фармакологический анализ сигнальных путей
Cross-layer evidence and calcium sensitivity analysis
illustrative hypergeometric p-value based on 63 strict BD protein-coding genes, 22 Tier 1 genes, and an HGNC universe of 19,296 genes; this is not a matched druggable-gene background
Comparison | Set size | Result | p-value / g:SCS-adjusted p | Contributing genes | Interpretation |
Exact strict BD-Tier 1 overlap | 80 raw / 22 | One shared symbol | 0.0695* | HTR6 | Not statistically compelling under the broad HGNC protein-coding background. |
Strict BD calcium result | 80 / 68 | No corrected calcium term | — | CACNA1B only in GO:0008331 | No robust disease-side enrichment under the strictest mapping. |
Functionally expanded BD calcium | 307 / 249 | GO:0008331 high voltage-gated calcium channel activity | 0.0486 | CACNA1B; CACNA1C; CACNB2 | Disease-side sensitivity signal. |
Tier 1 calcium | 22 / 22 | KEGG:04020 Calcium signaling pathway | 4.15 × 10⁻⁶ | ADRA1A; ADRA1B; CHRM1; HRH1; HTR2A; HTR2C; HTR6; HTR7 | Broad receptor-mediated drug-side signal. |
Tier 1 + Tier 2 calcium | 24 / 24 | KEGG:04020 Calcium signaling pathway | 4.52 × 10⁻⁷ | Tier 1 genes plus CACNA1E | Signal retained when the Tier 2 calcium-channel mechanism was added. |
Exact shared significant calcium annotation | BD vs drug layers | None | — | — | Supports thematic relatedness, not formal pathway convergence. |